Chairman of the board
Dr. Mahdi Al Fardan is a distinguished pediatrician and accomplished businessman, blending medical expertise with entrepreneurial insight. A graduate of the Mount Sinai School of Medicine in the US, he has focused his career on advancing pediatric healthcare with compassion and modern practices. As Chairman of the Gulf International Cancer Center, Dr. Al Fardan drives strategic initiatives that enhance cancer care offerings, ensuring cutting-edge, patient-centered treatments. In addition to his medical role, he plays significant roles within the Alfardan Group and First Investor Group, reflecting his commitment to innovation and excellence in both healthcare and business.Founder & Chief Radiation Oncologist
Dr. Abdel Razek graduated from Cairo University and completed his residency in 1976 at Washington University in St. Louis, Mo., USA. He is board certified in Radiation Oncology and has co-authored four textbooks in the field, along with contributing to numerous publications in oncology journals. He has served on national committees for the Southwest Oncology Group, Intergroup Ewings Sarcoma, and National Wilms Tumor Committee. Dr. Abdel Razek is a Fellow of the American College of Radiation Oncology and currently serves as Executive Director and Chief of Radiation Oncology at the Gulf International Cancer Center.MA, MBBChir, PhD, FRCR, FRCP, FFPM Chief Medical Director, Proton Partners International Ltd.
Professor Karol Sikora is a renowned British oncologist and a leading authority on cancer. He is the founder and Medical Director of Rutherford Health, specializing in proton therapy. A former head of the World Health Organization’s cancer program, Sikora has published over 300 papers and authored or edited 20 books, including Treatment of Cancer textbook. Recently, his work with Amethyst Radiotherapy has focused on advancing cancer treatment protocols and improving radiotherapy techniques.